PTEN loss and KRAS activation cooperate in murine biliary tract malignancies

Journal of Pathology

Volumn 230, Issue 2, 2013, Pages 165-173

  Marsh, Victoria ^a   Davies, Emma J ^a   Williams, Geraint T ^b   Clarke, Alan R ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

biliary tract malignancy; KRAS; mouse model; PTEN

Indexed keywords

BETA GALACTOSIDASE; K RAS PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B;

ANIMAL EXPERIMENT; ARTICLE; BILE DUCT; BILE DUCT CARCINOMA; CANCER SURVIVAL; CONTROLLED STUDY; ENZYME ACTIVATION; GALLBLADDER CARCINOMA; GENE MUTATION; HISTOLOGY; IMMUNOHISTOCHEMISTRY; LIVER CELL; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL;

ANIMALS; ANIMALS, OUTBRED STRAINS; BILE DUCT NEOPLASMS; BILIARY TRACT; CHOLANGIOCARCINOMA; EPITHELIAL CELLS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; GENE DELETION; GENE EXPRESSION REGULATION, NEOPLASTIC; KAPLAN-MEIER ESTIMATE; MALE; MICE; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; MUTATION; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS P21(RAS); PTEN PHOSPHOHYDROLASE; SURVIVAL RATE;

EID: 84877781677     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.4189     Document Type: Article

References (30)

1. Anderson CD, Pinson CW, Berlin J, et al,. Diagnosis and treatment of cholangiocarcinoma. Oncologist 2004; 9: 43-57.
2. Khan SA, Davidson BR, Goldin R, et al,. Guidelines for the diagnosis and treatment of cholangiocarcinoma: consensus document. Gut 2002; 51 (suppl 6): VI 1-9.
3. Li J, Yen C, Liaw D, et al,. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997; 275: 1943-1947.
4. Steck PA, Pershouse MA, Jasser SA, et al,. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet 1997; 15: 356-362.
5. Stambolic V, Suzuki A, de la Pompa JL, et al,. Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell 1998; 95: 29-39.
6. Pignochino Y, Sarotto I, Peraldo-Neia C, et al,. Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas. BMC Cancer 2010; 10: 631.
7. Herberger B, Puhalla H, Lehnert M, et al,. Activated mammalian target of rapamycin is an adverse prognostic factor in patients with biliary tract adenocarcinoma. Clin Cancer Res 2007; 13: 4795-4799.
8. Xu X, Kobayashi S, Qiao W, et al,. Induction of intrahepatic cholangiocellular carcinoma by liver-specific disruption of Smad4 and Pten in mice. J Clin Invest 2006; 116: 1843-1852.
9. Malumbres M, Barbacid M,. RAS oncogenes: the first 30 years. Nat Rev Cancer 2003; 3: 459-465.
10. Kodaki T, Woscholski R, Hallberg B, et al,. The activation of phosphatidylinositol 3-kinase by Ras. Curr Biol 1994; 4: 798-806.
11. Bos JL,. ras oncogenes in human cancer: a review. Cancer Res 1989; 49: 4682-4689.
12. Abraham SC, Lee JH, Hruban RH, et al,. Molecular and immunohistochemical analysis of intraductal papillary neoplasms of the biliary tract. Hum Pathol 2003; 34: 902-910.
13. Nakanuma Y, Harada K, Ishikawa A, et al,. Anatomic and molecular pathology of intrahepatic cholangiocarcinoma. J Hepatobil Pancreat Surg 2003; 10: 265-281.
14. Kim YT, Kim J, Jang YH, et al,. Genetic alterations in gallbladder adenoma, dysplasia and carcinoma. Cancer Lett 2001; 169: 59-68.
15. Isa T, Tomita S, Nakachi A, et al,. Analysis of microsatellite instability, K-ras gene mutation and p53 protein overexpression in intrahepatic cholangiocarcinoma. Hepatogastroenterology 2002; 49: 604-608.
16. Tada M, Omata M, Ohto M,. Analysis of ras gene mutations in human hepatic malignant tumors by polymerase chain reaction and direct sequencing. Cancer Res 1990; 50: 1121-1124.
17. Tada M, Omata M, Ohto M,. High incidence of ras gene mutation in intrahepatic cholangiocarcinoma. Cancer 1992; 69: 1115-1118.
18. Kiba T, Tsuda H, Pairojkul C, et al,. Mutations of the p53 tumor suppressor gene and the ras gene family in intrahepatic cholangiocellular carcinomas in Japan and Thailand. Mol Carcinog 1993; 8: 312-318.
19. Mullany LK, Fan HY, Liu Z, et al,. Molecular and functional characteristics of ovarian surface epithelial cells transformed by KrasG12D and loss of Pten in a mouse model in vivo. Oncogene 2011; 30: 3522-3536.
20. Richards JS, Fan HY, Liu Z, et al,. Either Kras activation or Pten loss similarly enhance the dominant-stable CTNNB1-induced genetic program to promote granulosa cell tumor development in the ovary and testis. Oncogene 2012; 31: 1504-1520.
21. Dinulescu DM, Ince TA, Quade BJ, et al,. Role of K-ras and Pten in the development of mouse models of endometriosis and endometrioid ovarian cancer. Nat Med 2005; 11: 63-70.
22. Iwanaga K, Yang Y, Raso MG, et al,. Pten inactivation accelerates oncogenic K-ras-initiated tumorigenesis in a mouse model of lung cancer. Cancer Res 2008; 68: 1119-1127.
23. Suzuki A, de la Pompa JL, Stambolic V, et al,. High cancer susceptibility and embryonic lethality associated with mutation of the PTEN tumor suppressor gene in mice. Curr Biol 1998; 8: 1169-1178.
24. Guerra C, Mijimolle N, Dhawahir A, et al,. Tumor induction by an endogenous K-ras oncogene is highly dependent on cellular context. Cancer Cell 2003; 4: 111-120.
25. Soriano P., Generalized lacZ expression with the ROSA26 Cre reporter strain. Nat Genet 1999; 21: 70-71.
26. Kemp R, Ireland H, Clayton E, et al,. Elimination of background recombination: somatic induction of Cre by combined transcriptional regulation and hormone binding affinity. Nucleic Acids Res 2004; 32: e92.
27. Backman SA, Ghazarian D, So K, et al,. Early onset of neoplasia in the prostate and skin of mice with tissue-specific deletion of Pten. Proc Natl Acad Sci USA 2004; 101: 1725-1730.
28. Horie Y, Suzuki A, Kataoka E, et al,. Hepatocyte-specific Pten deficiency results in steatohepatitis and hepatocellular carcinomas. J Clin Invest 2004; 113: 1774-1783.
29. Komuta M, Spee B, Vander Borght S, et al,. Clinicopathological study on cholangiolocellular carcinoma suggesting hepatic progenitor cell origin. Hepatology 2008; 47: 1544-1556.
30. Komuta M, Govaere O, Vandecaveye V, et al,. Histological diversity in cholangiocellular carcinoma reflects the different cholangiocyte phenotypes. Hepatology 2012; 55: 1876-1888.